- Home
- FOFO vs KZIA Comparison
FOFO vs KZIA Comparison
Compare FOFO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOFO | KZIA |
|---|---|---|
| Founded | 2017 | 1994 |
| Country | Hong Kong | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.2M | 93.2M |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | FOFO | KZIA |
|---|---|---|
| Price | $4.60 | $7.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 24.0K | ★ 123.5K |
| Earning Date | 03-13-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.09 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.86 | $0.64 |
| 52 Week High | $68.00 | $17.40 |
Technical Indicators
Market Signals| Indicator | FOFO | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 50.42 | 49.78 |
| Support Level | $2.86 | $6.44 |
| Resistance Level | $6.09 | $8.05 |
| Average True Range (ATR) | 0.61 | 0.71 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 31.66 | 37.28 |
Price Performance
Historical ComparisonAbout FOFO Hang Feng Technology Innovation Co. Ltd. Ordinary Shares
Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their unique business and investment objectives. Its business consists of two main segments: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting, and Regulatory compliance and governance consulting.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.